Toshiba Corporation announced the development of a highly sensitive electrochemical DNA chip that is able to detect DNA at very low concentrations.
The new chip integrates complementary metal oxide semiconductor (CMOS) circuits, one of the most widely used semiconductor-circuit technologies, with its sensors. It is the latest addition to Toshiba's advanced line-up of DNA chips and related technologies, and immediate applications will include analysis of susceptibility to anticancer drugs and health monitoring for preventative identification of disease genesis.
Toshiba announced its first electrochemical DNA chip in October 2001, a device that used an original current detection method to support development of individual treatment regimes for patients infected with hepatitis C. Jointly developed with a team from the Graduate School of Pharmaceutical Sciences of Osaka University, led by Professor Junichi Azuma, the chip supports investigation of treatment efficacy and side effects for individual patients. This research covered six areas of illness: tuberculosis, digestive disorders, ademonia, hyperlipemia, cardiac arrest and cancer.
Rohm and Ushio have developed the world's first biochip-based liver function testing system
Rohm has announced that it has developed a compact liver function testing system in collaboration with Ushio.
The system combines Rohm's proprietary biochip, which integrates microchannels and a micromixer on a single chip 2.6cm in diameter, with Usio's unique compact blood analyzer, and quickly identifies liver markers such as gamma-GTP.